COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effect of Metabolic Therapy in Patients With Chronic Ischemic Heart Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00282360
Recruitment Status : Completed
First Posted : January 26, 2006
Last Update Posted : January 26, 2006
Information provided by:
IRCCS San Raffaele

Brief Summary:
Patients with coronary artery disease have an abnormal cardiac metabolism. The hypothesis of this study is that shifting cardiac metabolism from free fatty acids to glucose will improve myocardial ischemia

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Type II Diabetes Mellitus Drug: Trimetazidine Phase 4

Detailed Description:

The present study will evaluate the effect of free fatty acid inhibition with Trimetazidine on silent myocardial ischemia and total ischemic burden in coronary artery disease patients with type II diabetes.

Patients will undergo ambulatory ECG monitoring at baseline and will be randomized to receive on top of thei standard anti-anginal therapy trimetazidine or placebo for 6 months. Patients will repeat the ambulatory ECG monitoring at the end of the study

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Effect of Metabolic Therapy in Patients With Chronic Ischemic Heart Disease
Study Start Date : February 1999
Study Completion Date : October 2003

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. total ischemic burden
  2. silent ischemia

Secondary Outcome Measures :
  1. symptomatic myocardial ischemia

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

coronary artery disease type II diabetes mellitus -

Exclusion Criteria:

unstable coronary artery syndromes impaired liver and kidney function


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00282360

Sponsors and Collaborators
IRCCS San Raffaele
Layout table for investigator information
Principal Investigator: Giuseppe Marazzi, MD H San Raffaele EUR
Layout table for additonal information Identifier: NCT00282360    
Other Study ID Numbers: SR05-1-5
First Posted: January 26, 2006    Key Record Dates
Last Update Posted: January 26, 2006
Last Verified: May 2004
Keywords provided by IRCCS San Raffaele:
coronary artery disease
diabetes mellitus
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Vasodilator Agents